Furthermore, LKB1 haploinsufficiency clearly accelerates KRAS–driven lung cancers in mice, where LKB1-deficient tumors demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumors mutated in Kras lacking p53 or p16Ink4a/p19Arf[19]. Here, CDKN2A is linked to lung cancer.